Literature DB >> 36255625

Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras.

Salma Darwish1,2, Tino Heimburg1, Johannes Ridinger3,4, Daniel Herp5, Matthias Schmidt1, Christophe Romier6, Manfred Jung5, Ina Oehme3,4, Wolfgang Sippl7.   

Abstract

Histone deacetylases are considered promising epigenetic targets for chemical protein degradation due to their diverse roles in physiological cellular functions and in the diseased state. Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS). One of the promising targets for this approach is histone deacetylase 6 (HDAC6), which is highly expressed in several types of cancers and is linked to the aggressiveness of tumors. In the present work, we describe the synthesis of HDAC6 targeting PROTACs based on previously synthesized benzohydroxamates selectively inhibiting HDAC6 and how to assess their activities in different biochemical in vitro assays and in cellular assays. HDAC inhibition was determined using fluorometric assays, while the degradation ability of the PROTACs was assessed using western blot analysis.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Epigenetic proteins; Histone deacetylase 6; Proteolysis-targeting chimeras

Mesh:

Substances:

Year:  2023        PMID: 36255625     DOI: 10.1007/978-1-0716-2788-4_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

Review 1.  Chemical Protein Degradation Approach and its Application to Epigenetic Targets.

Authors:  Yukihiro Itoh
Journal:  Chem Rec       Date:  2018-06-12       Impact factor: 6.771

Review 2.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

3.  Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.

Authors:  Takumi Sakuma; Katsuhiro Uzawa; Takeshi Onda; Masashi Shiiba; Hidetaka Yokoe; Takahiko Shibahara; Hideki Tanzawa
Journal:  Int J Oncol       Date:  2006-07       Impact factor: 5.650

Review 4.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

5.  Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

Authors:  C A Bradbury; F L Khanim; R Hayden; C M Bunce; D A White; M T Drayson; C Craddock; B M Turner
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

6.  Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.

Authors:  Hao Wu; Ka Yang; Zhongrui Zhang; Eric D Leisten; Ziyuan Li; Haibo Xie; Jin Liu; Kerry A Smith; Zora Novakova; Cyril Barinka; Weiping Tang
Journal:  J Med Chem       Date:  2019-07-17       Impact factor: 7.446

Review 7.  Targeted Protein Degradation: from Chemical Biology to Drug Discovery.

Authors:  Philipp M Cromm; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-06-22       Impact factor: 8.116

8.  [Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma].

Authors:  Lin-lin Yuan; Feng Wang; Sheng-lei Li; Wei-hua Lou; Liu-xing Wang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-06

Review 9.  HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions.

Authors:  Agustín Valenzuela-Fernández; J Román Cabrero; Juan M Serrador; Francisco Sánchez-Madrid
Journal:  Trends Cell Biol       Date:  2008-05-09       Impact factor: 20.808

10.  Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.

Authors:  Younghee Park; Kyu Sang Lee; So Yeon Park; Jee Hyun Kim; Eun Young Kang; Sung Won Kim; Keon Young Eom; Jae Sung Kim; In Ah Kim
Journal:  J Breast Cancer       Date:  2015-09-24       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.